Anti-Human Fractalkine

Pricing & Details

Product No.C1306
Protein
Fractalkine
Formats AvailableView All
Product Type
Polyclonal Antibody
Alternate Names
CX3CL1, NTN, ABCD-3, C3Xkine, CXC3, CXC3C, NTT, SCYD1, Neurotactin, FKN
Applications
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
C1306-20ug
20 µg
$195.00
In stock
Max:
Min: 1
Step: 1
C1306-0.1 mg
0.1 mg
$397.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Rabbit
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti-Human Fractalkine (FKN) recognizes Human FKN. This polyclonal antibody was purified using affinity chromatography.
Background
Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium1 that mediates attachment and firm adhesion of T cells, monocytes and NK cells.2 FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.3 FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).4

Antigen Details

References & Citations

1. Patel DD et al. (1998) J Exp Med. 188: 1413 2. Hwang ST et al. (1999) Eur J Immunol. 29: 2551 3. Muller GA et al. (2008) Z Rheumatol. 67: 424 4. Mori M et al. (2005) Int J Oncol. 26: 41
General Western Blot Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok